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Background: Pro-inflammatory molecules and low-density lipoproteins play essential roles in the atherosclerosis.
The aim of our study was to establish an association among the cytokines secreted by peripheral blood
mononuclear cells and the serum concentration in patients with unstable angina and coronary outward remodeling
before and after percutaneous coronary intervention. The clinical and coronary responses were evaluated 6 months
after the procedure.
Findings: Twenty-two patients with unstable angina were evaluated prior to after percutaneous coronary
intervention and 6 months after procedure by coronary intravascular ultrasound. Eleven of the patients had
recurrent angina, while 9 presented restenosis and an increase in the percentage of total plaque area. These 11
patients displayed higher levels of C-reactive protein than those without coronary events (1.27 vs. 0.43 mg/dl,
respectively; p = 0.029) and a tendency to increase levels of interleukin (IL)-8 and transforming growth factor-β1, but
lower levels of IL-10 (52.09 vs. 141.5 pg/ml, respectively; p = 0.035). Activated peripheral blood mononuclear cells
from patients with restenosis presented higher levels of proliferation, CD86 expression and higher IL-1, and
increased IL-10 compared to those in patients without restenosis.
Conclusions: Patients with unstable angina and coronary outward remodeling who displayed a pro-inflammatory
response experienced recurrent coronary events and an increased percentage of total plaque area. In contrast,
better outcomes were observed in patients with anti-inflammatory responses. This response could be secondary to
low-density lipoproteins.
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Background
The development and progression of coronary atheroscler-
otic lesions are characterized by lipid accumulation, cellular
proliferation, and an inflammatory response, all of which
causes changes in the vascular arterial wall [1]. These pro-
cesses determine the plaque vulnerability, severity of lumen
obstruction, and homodynamic and ischemic myocardial* Correspondence: fblanco1@terra.com.mx
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article, unless otherwise stated.repercussion [2,3]. Necropsy studies have demonstrated
that lesion with positive or outward remodeling has higher
lipid contents, as well as macrophage and other inflamma-
tory cells counts, both markers of plaque vulnerability [4].
It seen that in patients with acute coronary syndrome,
lipid accumulation in a culprit lesion is related with vascu-
lar expansion in atherogenesis. Additionally, remodeling
of the arterial wall is an important mechanism in re-
stenosis after percutaneous coronary interventions [3].
Angiographic follow-up studies have associated inflamma-
tory activity with the frequency of restenosis, supported
by the presence of inflammatory cells such as monocytes
and T cells in the restenotic lesions [5,6].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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response has been controversial. Some of the possible
triggers of the inflammatory response include Helicobacter
pylori, Chlamydia pneumoniae and modified low-density
lipoprotein (LDL) cholesterol [1,7]. Several studies have
demonstrated that different forms of oxidized low-density
lipoproteins (oxLDL) contribute to the development of
atherosclerotic lesions through an inflammatory re-
sponse [8,9], supporting the idea that oxLDL may be a
key antigen in atherosclerosis [7].
In addition, some studies have demonstrated that oxLDL
activates different cell types and induces the secretion of
pro-inflammatory interleukins (IL) such as IL-1β and IL-6
[10]. Others have shown that the T cells from patients with
unstable angina (UA) can be activated with oxLDL; in con-
trast, T cells from stable patients exhibit a lower response
to oxLDL [11]. Furthermore, native LDL (nLDL) increases
the generation of vascular endothelial superoxide anions
in situ, suggesting that it plays a role in the premature
development of atherosclerosis [12].
However, specific mechanisms and temporal course of
the complex interplay between mechanical dilatation, in-
flammatory response and corresponding changes in arterial
anatomy and physiology are still poorly understood.
The aim of this study was to determine whether there
is an association between the type of cytokines secreted
from peripheral blood mononuclear cells (PBMCs) ac-
tivated with nLDL in vitro and the serum cytokines
concentrations, from patients with unstable angina and
coronary outward remodeling before and after intravascu-
lar ultrasound-guided percutaneous coronary intervention
(PCI), and the clinical and coronary responses were evalu-
ated 6 months after the procedure.
Methods
Patient population
This study included 22 patients with unstable angina
who were admitted to the Coronary Care Unit of the
Hospital de Cardiología, Centro Médico Nacional “Siglo
XXI”. All of the patients were stable and had not experi-
enced angina within the 48 hours before the procedure.
Informed consent was obtained from all patients and
healthy donors. The study was approved by the Human
Ethics and Medical Research Committee of the Instituto
Mexicano del Seguro Social (IMSS) and was conducted
according to the Helsinki Declaration guidelines. The
inclusion criteria included the following: a) patients
younger than 75 years of age; b) angina duration less
than 30 minutes, associated with an ST-segment depression
of more than 1 mm or dynamic T wave changes at rest
electrocardiogram during angina and no evidence of
myocardial infarction detected with enzyme markers
(MB creatine kinase and troponin I); c) patients eligible
for percutaneous coronary intervention (PCI) with abare metal stent implantation; d) it was necessary to confirm
the presence of positive (or outward) artery remodeling
at the culprit lesion with intravascular ultrasound images
before coronary intervention. The exclusion criteria in-
cluded the following: patients with recent bypass sur-
gery or previous PCI; patients with left bundle branch
block that invalidated ST-segment analysis, known ma-
lignancies, hematological and immunological disorders,
any other inflammatory conditions or infections likely
to be associated with the acute phase response, previous
immunosuppressive or anti-inflammatory therapy, serum
creatinine ≥1.5 mg/dl or known allergic reactions to
iodine contrast medium. All patients received optimal
anti-ischemic therapy (dual antiplatelet therapy with
aspirin and clopidogrel, unfractionated heparin, intravenous
nitroglycerine, beta blockers and statins), calcium channel
blockers and ACE inhibitors, as required for each patient.
All patients underwent laboratory tests, including those
to measure total cholesterol, triglycerides, high density
lipoprotein cholesterol, cholesterol LDL, white blood
cell counts, creatinine and C-reactive protein.
Twelve healthy, normolipemic, 30- to 40-year-old volun-
teers without cardiovascular risk factors or clinically appar-
ent atherosclerotic disease were also included as controls.
Coronary angiography and intravascular ultrasound
All patients underwent coronary angiography under the
same conditions. The culprit lesion was defined by a signifi-
cant stenosis >50%, abnormal thrombolysis in a myocardial
infarction (TIMI) flow grade of 1 or 2, or an intra-luminal
defect strongly suggestive of a thrombus in the vessel
lesion. The restenosis was defined as stenosis of ≥50%
observed at the 6-month follow-up of the target lesion.
Intravascular ultrasound (IVUS) studies were performed
using a commercially available CVI-INSIGHT system
(Cardiovascular Imaging Systems, Inc.). In brief, this
system consisted of a single-element 40 mHz transducer
mounted on the tip of a flexible beveled shaft within a 3.2
Fr short monorail polyethylene imaging sheath to allow the
formation of planar images in real time. Prior to the IVUS
studies, all patients received intracoronary nitroglycerine
(200 μg). The IVUS catheter was advanced 10 mm distal to
the culprit lesion site. Studies were recorded for off-line ana-
lysis, as previously reported [3,13]. This recording was used
to identify the corresponding image on the postintervention
and control studies at the 6-month follow-up. The IVUS
studies were performed in the same angiographic projection
of the culprit lesion, and with data collected from the axial
landmark (aorto-ostial junction to the target lesion), as
reported previously [13].
Quantitative coronary analysis
Quantitative IVUS analysis included measurements of
the external elastic membrane (EEM), cross-sectional
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(P&M), percent plaque area and cross-sectional narrow
(CSN). Measurements were taken at the site of the target
lesion and in a proximal segment of the culprit artery,
and the analysis was performed as previously reported
[13]. The EEM CSA at the culprit lesion was compared
to a proximal reference with the most normal-looking CSA
(within 10 mm proximal). Outward remodeling was defined
as lesion external elastic membrane (EEM) cross-sectional
area (CSA) greater than the proximal reference.
Percutaneous coronary intervention
PCI with bare metal stent implantation in the target lesion
was guided with IVUS. Procedure was considered success-
ful if the final percentage of the residual stenosis was <30%
with a TIMI flow grade of 3 in the absence of recurrent
myocardial ischemia, myocardial infarction, need of urgent
coronary bypass surgery or death during the hospitalization
period. A 6-month follow-up was performed in all pa-
tients unless the patient presented clinical indications
for coronary angiography before this period of time. All
of the angiograms and IVUS images were re-analyzed by
two experienced, blinded cardiologists. An inter-observer
variability with a kappa proportion of 0.83 was observed.
LDL isolation
Native LDL (nLDL) (density 1.019-1.063 g/ml) was
isolated by sequential ultracentrifugation from the
plasma of UA patients who were not candidates for
PCI and from normolipemic donors. The plasma dens-
ity was adjusted to 1.2 g/ml by the addition of solid KBr
(J.T. Baker, Phillipsburg, NJ, USA). The plasma solution
was then distributed into polycarbonate centrifuge tubes,
and a discontinuous density gradient was created by overlay-
ing the plasma solution (3 ml) with 3 ml each of the follow-
ing densities: 1.065 g/ml, 1.020 g/ml, and 1.006 g/ml.
The tubes were ultracentrifuged in a Beckman LX-90
ultracentrifuge equipped with an SW 40 Ti rotor at
30,000 rpm for 22 hours at 4°C. After ultracentrifugation,
the low-density lipoprotein was removed. The LDL frac-
tion was dialyzed against phosphate-buffered saline (PBS)
containing 0.01 M phosphate (J.T. Baker, NJ, USA), 0.5 M
NaCl (Caledon Laboratories Ltd, Ont, Canada), and
0.5 mM EDTA (Sigma, St. Louis, MO, USA), pH 7.4,
for 24 hours at 4°C. The degree of oxidation of nLDL
from patients and healthy donors was assessed by
measuring thiobarbituric acid-reactive substances as
previously described [14].
Flow cytometry
PBMCs were isolated from UA patients (before and
6 months after PCI) by density centrifugation using
Lymphoprep (Axis-Shield, Liverpool, UK). The PBMCs
were recovered from the interface, washed three timeswith PBS (pH 7.4) and resuspended in RPMI (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% fetal bovine
serum (FBS) (Invitrogen, Carlsbad, CA, USA). Subsequently,
the PBMCs (2×105/ml) were treated with 10 μg/ml of nLDL
obtained from patients and healthy donors. As a negative
control, PBMCs were cultured with RPMI (Invitrogen)
supplemented with 10% FBS (Invitrogen). For a positive
activation control, PBMCs were plated at 2×105/ml in
96-well flat-bottomed tissue culture plates coated with
anti-CD3 (BD Biosciences, CA). Regardless of treatment, all
cells were incubated for 18, 24, 72 and 168 hours at 37°C.
The PBMCs were then stained with antibodies specific for
CD4, CD25, CD69, and CD86 or with isotype-control anti-
bodies (all from BD Biosciences) for 20 minutes in the dark
at 4°C. The cells were then washed three times with PBS,
fixed with 2% paraformaldehyde, and analyzed using a
FACS Calibur flow cytometer (BD Biosciences).
Proliferation assays
PBMCs of UA patients were isolated prior to PCI and
6 months after PCI by density centrifugation using
Lymphoprep (Axis-Shield). The PBMCs were recovered
from the interface, washed three times with PBS (pH 7.4)
and resuspended in RPMI (Invitrogen) supplemented with
10% FBS (Invitrogen). The PBMCs (2×105/ml) were then
treated with 10 μg/ml of nLDL obtained from patients
and healthy donors. As a negative control, PBMCs were
cultured with RPMI (Invitrogen) containing 10% FBS
(Invitrogen) and for a positive control, the cells were
cultured with anti-CD3 (BD Biosciences). After 3 days,
the cells were pulsed with 1 uCi [3H] thymidine (GE
Healthcare, Uppsala, Sweden) for an additional 3 days. The
PBMCs were harvested into glass fiber filters, and the [3H]
thymidine (GE Healthcare) incorporation was measured
using a scintillation counter (Packard 1900TR counter).
Cytokine assay
PBMCs (1×106/ml) from patients with UA (isolated prior to
PCI and 6 months after procedure) were incubated with
10 μg/ml nLDL obtained from patients and healthy donors.
Concanavaline A (Sigma) was used as a positive control. As a
negative control, the PBMCs were cultured with medium
alone. The culture supernatants were collected after 18, 24
and 72 hours and 7 days of incubation at 37°C. Additionally,
sera were obtained from patients (prior to PCI and 6 months
after PCI) for the measurement of cytokines. The levels of IL-
1, IL-8, IL-10, and TGF-β in the supernatants and sera were
analyzed using commercial enzyme-linked immunosorbent
assay (ELISA) kits (Biosource International, Camarillo,
CA, USA) according to the manufacturer’s instructions.
Statistical analysis
Because the results were not normally distributed, were
expressed as medians and percentiles or ranges. Depending
Table 1 Distribution of demographic characteristics and
risk factors between patients
Recurrent agina or restenosis
Yes (n=11) No (n=11)






Previous angina 7 7
Previous MI 3 2
Ejection fraction % 58.2 (49-75) 51 (40-75)
Angiography
1 vessel 7 5
2 vessels 3 5
3 vessels 1 1
Systemic hypertension was the only risk factor that was significantly
associated with recurrent ischemic events (*p = 0.027).
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divided into two groups, those with recurrent angina
or restenosis and those without recurrent events.
Qualitative variables (dichotomy variables) were analyzed
using the Chi-square test or Fisher’s exact test. Nonpara-
metric Wilcoxon tests were performed for quantitative
paired variables (before and 6 months after PCI). Mann–
Whitney U tests were used to compare independent groups
(patients with and without recurrent angina or restenosis),
and the association between inflammatory markers and
clinical outcome was tested using Spearman’s rho correl-
ation coefficient. A one-tailed p-value of ≤0.05 was consid-
ered significant with a 95% CI.
Results
Patient characteristics
The patients’ median age was 61 years (range: 50 to
73 years old), and the sample included 14 men and 8
women. Of these, 7 had diabetes, 10 had systemic arterial
hypertension, 14 were smokers, and 11 had dyslipidemia.
All patients had experienced angina events previous to
hospitalization, and 8 had prior myocardial infarctions. All
patients were admitted with unstable angina considered
intermediate or high risk.
Intravascular ultrasound imaging
Correlation of angiographic results with clinical
presentation and IVUS results
The coronary angiography showed that 12 patients had
single-vessel coronary disease, 8 had 2-vessel disease,
and 2 had 3-vessel disease. The anterior descending artery
was the most frequent culprit vessel (17 patients), while
the culprit was the left circumflex in 3 cases and the right
coronary in 2 patients. The most frequent target lesion
type was B (5 patients with type B1 and 12 with type B2);
in 5 cases we identified a type C lesion. No significant dif-
ferences in the type and severity of the coronary artery
diseases between patients with or without recurrent ische-
mic events were observed. Qualitative analysis with IVUS
showed that fibrolipidic-like atherosclerotic lesions were
observed in the culprit vessel (11 cases) more often than
lipidic (6 cases) or fibrotic (5 cases) lesions. In 9 patients,
the imaging suggested calcium plaque (less than 90° of
the vessel circumference), with severe calcium deposition
(more than 180°) in just 1 patient. Quantitative analysis
was performed for all patients. The median EEM CSA was
16.3 mm2 (range: 10.5-25.7 mm2). The median vessel
diameter was 4.5 mm (range: 3.5-5.7 mm). The median
lumen CSA was 2.2 mm (range: 1.8-2.8 mm), and the
median CSN was 72.2% (range: 54.3- 83.8%). There were
no differences observed between patients with recurrent
angina or restenosis and patients without recurrent is-
chemia at the time of follow-up. Only 1 patient pre-
sented coronary spasm as a complication of IVUS, andthis was resolved with an intracoronary administration
of verapamil and nitroglycerine. Angiographic success
was obtained in all patients after the procedure, only 2
patients required 2 stents due to the length of the ath-
erosclerotic plaque, but was not associated with recurrent
ischemic events.
At the 6-month follow-up, 11 patients had recurrent
angina. Of these, we identified restenosis of the target
lesion by coronary angiography in 9 cases (left descending
artery in 8 patients and circumflex in 1 patient). The car-
diovascular risk factors and TIMI risk score were similarly
distributed among patients with a new angina episode and
patients without events. Systemic hypertension was the only
risk factor that was significantly associated with recurrent
ischemic events (p = 0.027, RR = 7.0, 95% CI 1.02 - 47.81)
(Table 1). No significant differences were found by quantita-
tive IVUS analysis of the EEM CSA at 6 months. We found
a significant increase (p = 0.015) in the plaque percentage
area in patients with restenosis (60.83% [50.9-70.6%])
compared to those without restenosis (48.25% [42.8-60%]).
The patients with restenosis also had significantly higher
(p = 0.075) CSN gains (8.48% [19.60 a – 11.8%]) than those
without restenosis (4.25% [23.9 – 3.2%]) and in two patients
was identified late stent malposition (Table 2). In addition,
the patients with restenosis presented important neointimal
hyperplasia (data not shown).
Determination of IL-8, CRP, IL-10, and TGF-β levels in the sera
We found a tendency of higher IL-8 concentrations before
intervention in patients with recurrent ischemic events
when compared to the group of patients without recurrent
Table 2 Quantitative IVUS image analysis in patients
Recurrent angina or restenosis
Yes No
Before PTCA
EEM CSA (mm2) 16.4 (10.5-25.7) 16. (12.5-18.9)
Lumen CSA (mm2) 4.23 (3.10-6.40) 4.95 (3.4-6.4)
Luminal diameter (mm) 2.1 (1.8-2.8) 2.3 (2.0-2.6)
CSN (%) 76.65 (57.4-83.8) 64.6 (54.3-77)
Lesion length (mm) 19.5 (15.1-22.2) 19.1 (12.7-21.9)
After PTCA
EEM CSA (mm2) 17.1 (10.2-25.7) 16.6 (12.8-21.4)
Lumen CSA (mm2) 8.9 (5.8-16.5) 8.95 (6.3-11.5)
Luminal diameter (mm) 3.15 (2.8-4.5) 3.25 (2.8-3.7)
CSN (%) 45.4 (36.10-62.3) 48.13 (43.7-62.7)
Lumen area gain (mm2) 5.05 (1-10) 3.75 (2.8)
Lumen diameter gain (mm) 1.10 (0-2) 0.91 (0-2)
6 months
Outward remodeling 5 pac. 4 pac.
ATV (mm2) 16.80 (10.5-24) 14.9 (10.0-23.5)
LUMEN CSA (mm2) 5.95 (3.9-9.1) 8.6 (6.0-12.0)
Luminal diameter (mm) 2.55 (2.1-3.2) 3.0 (2.5-3.9)
CSN (%) 60.83 (50.9-70.6)** 48.25 (42.8-60)**
Lumen CSA lost (mm2) -1.40 (-0.2 a -3.2) -0.55 (-0.2 a -6.6)
CSN gain 8.48 (-11.8 a 19.60) 4.25 (-3.2 a 23.9)
The results from quantitative IVUS image analysis are similar between patients
with and without recurrent ischemic events during follow-up. A significant
increase in percent plaque area (CSN) was observed in patients with restenosis
at the 6-month follow-up (**p = 0.015 by Mann–Whitney U test).
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(24.19 pg/ml [9.15 - 77.49 pg/ml] in patients with recur-
rent events vs. 10.01 pg/ml [2.70 - 46.76 pg/ml] in those
without recurrent events; correlation coefficient 0.408,
p = 0.07). The same tendency was found at the 6-month
follow-up (11.9 pg/ml [4.85 - 42.28 pg/ml] in patients with
favorable outcomes vs. 24.84 pg/ml [2.40-50.63 pg/ml] in
patients with recurrent angina or restenosis, p =NS). More-
over, of the patients presenting elevated levels of C reactive
protein, 9 of these had recurrent angina events or restenosis
(1.27 mg/dl [0.27-2.3 mg/dl] in patients with recurrent
events vs. 0.43 mg/dl, [0.01 - 0.8 mg/dl] in patients without
events at 6 months, p =0.029). The IL-10 levels were higher
in patients without recurrent events compared to those
with recurrent events (141.5 pg/ml [36.47 - 271.30 pg/ml]
and 52.09 pg/ml [0.93 - 75.79 pg/ml], respectively; RR
0.25, 95% IC [0.075 – 0.83], p = 0.035). However, at the
6-month follow-up, both groups displayed similar values
(55.59 pg/ml [23.54-278.30 pg/ml] in the patients without re-
current ischemic events vs. 48.59 pg/ml [9.03-102.72 pg/ml]
in those with recurrent ischemic events, p =NS). Moreover,
we found an inverse correlation between the plasma levels ofIL-10 and the concentration of CRP (Spearman’s rho
correlation coefficient 0.477, p =0.05). In contrast, patients
with recurrent ischemic events or restenosis of the tar-
get lesion had higher levels of TGF β1 (1139.66 pg/ml
[632.43 - 1902.45 pg/ml]) than patients with better out-
comes (854.71 pg/ml [161.44 - 1413.83 pg/ml]), although
this difference was not statistically significant. At the
6-month follow-up, the TGF β1 levels were similar in both
groups of patients (1058.388 pg/ml [392.53- 2128.65 pg/ml]
in those with recurrent ischemic events and 1006.49 pg/ml
[566.83 - 2380.30 pg/ml] in those without recurrent events,
p =NS) (Figure 1).
Surface expression of CD69, CD25, and CD86 on PBMCs
Before PCI, the CD69 expression was 2.57% [0.98 - 11.51%]
on the PBMCs from patients with recurrent angina or
restenosis, compared to 1.27% [0.91 - 13.24%] on those
from patients without recurrent angina or restenosis
(p = NS). The CD25 expression in these groups was 8.5%
[0.10 - 16.72%] and 15.06% [6.62 - 25.07%], respectively
(p = NS). Similar results were found 6 months after coronary
intervention in both groups. In contrast, CD86 expression
remained elevated at the 6-month follow-up, principally
in those patients with recurrent ischemic events (12.17%
[8.03 - 78.92%] vs. 5.15% [3.43-62.56%] in those without
recurrent events prior to PCI and 38.38% [7.65-68.14%] in
those with recurrent events vs. 10.47% [6.85-44.46%] in
those without recurrent events at 6 months following PCI.
PBMC proliferation in response to LDL
We also investigated the effect of nLDL obtained from
patients and healthy donors on the proliferation of PBMCs.
As shown in Figure 2, the level of [3H] TdR uptake was
relatively low (1800 cmp [145–8,148]) in the negative
control. In contrast, in the presence of LDL, the PBMCs
of patients without recurrent angina or restenosis showed
an increased proliferative response compared with the
PBMCs cultured with medium alone. Moreover, the
proliferative response to LDL was similar in all patients,
although there was a tendency toward higher proliferation
levels in the PMBCs from patients with recurrent angina
or restenosis compared to those from patients without
recurrent angina or restenosis (in response to nLDL
obtained from patients: 6,717 cmp [199–62,311] vs. 4,342
cmp [1,215-15,225], respectively; in response to nLDL
obtained from healthy donors: 5,992 cmp [260–28,163]
vs. 4,653 cmp [1,097-27,245], respectively) (Figure 2).
Activation of PBMCs in response to LDL
We found that the expression of CD86 on PBMCs was el-
evated at different times in response to LDL in all patients,
particularly in the PBMCs from patients with recurrent
angina or restenosis at follow-up (24.94% [0.89-91.63%]),
compared to the patients without recurrent events
Figure 1 Comparison of basal and 6-month follow-up serum concentrations of IL-8, IL-10 and TGF β1, in patients with and without
recurrent ischemic events or restenosis. Patients without recurrent events displayed higher levels of IL-10 (p = 0.012) than those with recurrent
events. Patients with recurrent events had a tendency to present higher levels of IL-8 than those without recurrent events, but this difference was
not statistically significant. No: recurrent angina or restenosis (rectangle open); Yes: with recurrent angina (rectangle closed).
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ferences in the expression of CD69 or CD25 on the
PBMCs of the patients following different lengths of
LDL stimulation. There was actually a slight decrease
in the expression of CD69 and CD25 following 48 hours
of LDL stimulation, and the expression levels were similar
at 7 days.IL-1 and IL-10 production by LDL-stimulated PBMCs
We found that the in vitro nLDL stimulation of PBMCs
from patients with or without restenosis resulted in in-
creased IL-1 secretion, with a similar pattern observed
at the 6-month follow-up. Conversely, increased IL-10
secretion was observed in activated PBMCs from the
patients without restenosis at baseline and follow-up,
Figure 2 Proliferative responses to LDL, expressed as [3H] thymidine incorporation. Comparison of cellular responses from patients
without recurrent angina (left) and those with ischemic events (right –YES-). At follow-up, the cells from patients with recurrent angina had a
tendency of higher proliferative responses (p = NS). 10 μg/ml of LDLH obtained from healthy donors (rectangle with diagonal lines); 10 μg/ml of
LDLP obtained from patients (cross line), N (negative control).
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the cells from patients with restenosis or angina (Figure 3).
Discussion
Different publications have demonstrated that acute
coronary syndrome can be characterized by unstable
angina, non-ST-segment or ST-segment elevation myocar-
dial infarction and chronic inflammation. It has also been
suggested that an autoimmune mechanism could contrib-
ute to the atherosclerotic plaque progression and instabil-
ity, where the oxidative modification of LDL played a
pivotal role. Among others, these mechanisms include the
increased expression of adhesion molecules on endothelial
cells, monocyte activation, and pro-inflammatory cytokine
secretion [15,16]. We found that patients with recurrent
ischemic events or restenosis had a predominant pro-
inflammatory response and an increased percentage of
total plaque area in the culprit vessel 6 months after PCI.
This ex vivo response was similar to the in vitro response
of PBMCs activated with nLDL. Positive peri-stent vascu-
lar remodeling has been associated with stent thrombosis
due to late acquired stent malposition and this has been
reported more frequent with drug eluting stent. This
situation was identified in only two patients as the cause
of recurrent ischemic event, but all our patients underwent
to bare metal stent implantation. Two mechanisms arethought to contribute to the development of late acquired
stent malposition: decreased plaque volume behind the
stent due to clot lysis or plaque regression, and positive
remodeling of the vessel wall [17].
In our study, the inflammatory response was measured
by elevated C reactive protein levels, and this was associated
with the recurrence of angina or restenosis at 6 months,
similar to previous reports [1,2,12,14-20]. We found a ten-
dency toward higher serum concentrations of IL-8 in those
patients with restenosis compared to those without resten-
osis, in agreement with previous reports that predominantly
pro-inflammatory responses are associated with poor prog-
noses [21]. However, we also observed that patients with
higher levels of IL-10 had reduced frequencies of restenosis.
IL-10 has been shown to have a modulatory effect on the
immune response (most likely on the Th2 phenotype); this
response indirectly inhibits the secretion of cytokines from
Th1 cells, which inhibits the expression of cellular adhesion
molecules and stimulates the production of granulocyte-
macrophage colony-stimulating factor, tissue factor and
fibrinogen, as well as the proliferation of smooth muscle
cells, cyclooxygenase 2 expression and cellular death
[19-22]. By immunohistochemical analysis, Mallat et al.
[23] demonstrated that low levels of IL-10 were associ-
ated with reduced nitric oxide production. Additionally,
other reports have shown that low levels of IL-10 inhibit
Figure 3 The interleukin concentrations were compared in the supernatants of cells from patients with recurrent angina or restenosis
(left) and from those without recurrent ischemic events (right). Basal and 6-month follow-up results were also compared. Higher IL-10
concentrations were found in the samples from patients with recurrent events compared to those from patients without recurrent events
(Median, 25th and 75th quartile). 10 μg LDLH = 10 μg/ml of LDL obtained from healthy donors (rectangle with diagonal lines); 10 μg LDLP = 10 μg/ml
of LDL from patients (rectangle with blocks); W/E: without stimulus (rectangle open).
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oxide while simultaneously protecting the ischemic and
reperfused myocardium by reducing the recruitment of
neutrophils [24-28]. The levels of this anti-inflammatory
cytokine (IL-10) could be protective by regulating the effect
of pro-inflammatory cytokines, reducing the possibility
that an unstable atherosclerotic plaque will form and
resulting in an improved prognosis [25]. Some other cy-
tokines, such as IL-4, IL-1 receptor agonist and TGF β1,
have anti-inflammatory effects. However, until now, the
role of TGF β1 has been unclear, as clinical studies of
this factor reported inconsistent results, with some as-
sociating elevated serum levels of activated TGF β1 with
increased severity of atherosclerotic coronary disease or
recurrent acute ischemic events and others reporting
the opposite. Other studies demonstrated that the admin-
istration of anti-TGF β1 antibodies reduced the neointimal
lesion area and inhibited the differentiation of Th17 cells,
which play a critical role in the formation of atheroscler-
otic plaques [27-29]. In our study, patients with recurrent
ischemic events or restenosis tended to display higher
levels of activated TGF β1, without an association with the
number of vessels involved in the disease. It is likely that
the secretion of activated TGF β1 leads to an increase
in the production of extracellular matrix and to plaqueprogression and disruption [25,29-33]. Moreover, we
found elevated basal serum concentrations of activated
TGF β1 and lower IL-10 levels in patients with recur-
rent angina events or restenosis of the target lesion at
the 6-month follow-up. This finding suggests that a
TH1 phenotype response before coronary intervention
was associated with restenosis at follow up, character-
ized by an increase in the percentage of total plaque
area and neointimal hyperplasia without changes in ar-
terial remodeling. There was no significant difference
in the type of immune response between patients with or
without recurrent ischemic events at 6 months after PCI.
During the acute phase of unstable angina, the immune
response could have prognostic value for percutaneous
coronary interventions.
We decided to compare the effects of native LDL from
patients and healthy donors, taking into account the
fact that patients had higher levels of lipid peroxidation
products and different LDL molecule characteristics, with
smaller molecules and higher concentrations of choles-
terol esters than healthy donors. Our results demonstrated
higher levels of PBMC proliferation in response to stimula-
tion with nLDL from patients with coronary artery disease
(LDLnP) compared to stimulation with nLDL from healthy
donors (LDLnH). Moreover, we analyzed CD86 expression
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stenosis had higher CD86 expression levels than those from
patients without restenosis. When we analyzed the bio-
logical effect of cellular activation with the two types of
nLDL, our results showed that LDLnP tended to result in
increased expression levels of CD86. It has been demon-
strated that the stimulation of antigen presenting cells with
oxLDL increases the expression of CD86 and that its inter-
action with CD28 induces the activation and proliferation
of T lymphocytes, as well as the secretion of cytokines such
as IFN-γ [31,32]. Furthermore, we found that the secretion
of IL-1β was higher when PBMC were stimulated with
LDLnP than with LDLnH. Previous reports have demon-
strated that minimally modified LDL is capable of inducing
the secretion of pro-inflammatory cytokines such as IL-1β
and IL-6 [31a33]. However, we observed that LDLnH and
LDLnP also induced IL10 secretion. Similar to our results,
other studies have demonstrated that differentially modified
forms of LDL induce RNA expression of IL10 and cytokine
secretion, as a possible regulatory mechanism of cellular ac-
tivation [34,35].Conclusions
The patients with acute coronary syndrome and outward
remodeling at the culprit lesion artery were found to
have a predominantly pro-inflammatory response, with
poorer responses to interventional coronary procedures
and increased frequencies of restenosis. Restenosis was
associated with an increase in the percentage of total plaque
area and a recurrence of angina events after 6 months. In
contrast, a predominantly anti-inflammatory response was
associated with protection and an improved outcome. It ap-
pears that LDL has pro-atherogenic properties and induces
CD86 expression as well as the secretion of cytokines like
IL-1β, which participate in the atherosclerotic process.
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